Department of Defense – FY19 Pre-announcement of the Tuberous Sclerosis Complex Research Program (TSCRP)

If  you wish to speak with The Conafay Group about developing a proposal for this program, please contact Dr. David Driscoll (dld5dt). The Department of Defense recently released a pre-announcement for its Tuberous Sclerosis Complex (TSC) Research Program, which is managed by the office of Congressionally Directed Medical Research Programs (CDMRP) https://cdmrp.army.mil/pubs/press/press, to allow investigators time […]

NIH – Progression Markers for Cognitive Impairment in Parkinson’s Disease Dementia (R01 Clinical Trial Not Allowed)

In 2011, the National Alzheimer’s Project Act (NAPA) allocated resources “to prevent and effectively treat Alzheimer’s by 2025.”  Since then, the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS) have held multiple research summits to assess the needs and opportunities relevant to this goal for Alzheimer’s Disease (AD) and […]

NIH – Development and Validation of Advanced Mammalian Models for Alzheimer’s Disease-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed)

Alzheimer’sdisease-related dementias (ADRD) are a group of progressive, neurodegenerative disorders with mid- to late-life onset, including Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), frontotemporal degeneration (FTD) and mixed etiology dementias (MED). Although the ADRD each have characteristic behavioral, cognitive and pathological features, symptomatic overlap and multiple neuropathological processes are common […]

NIH – Implementation of shared decision making for HLBS diseases and conditions (R01 Clinical Trial Optional)

The purpose of this new FOA is to support research that uses evidence-based, practical approaches to increase the uptake of shared decision making (SDM) into routine clinical practice. Proposed projects must consider using available, proven-effective SDM strategies, tools, and curricula to the extent feasible. Utilization of evidence-based theoretical or conceptual frameworks for implementation science (e.g., […]

NIH – Botanical Dietary Supplements Research Centers (BDSRC) (U19 Clinical Trial Optional)

Plants and plant-derived products are widely consumed for basic nutrition, and to promote health and well-being, worldwide and in the U.S. Nevertheless, there is only a partial understanding of what effects (beneficial or adverse) many of these products have on human health and well-being. To the extent that these products may have clinical efficacy, the […]

NIH/NHLBI – NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)

The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards, of which one must be an NHLBI-funded NIH Early Stage Investigator R01 award, and whose outstanding record […]

NIH/NHLBI – NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)

The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Director/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, […]

NIH/NIDDK – Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Obesity Research (U01 Clinical Trial Not Allowed)

Many assays in basic and clinical science research rely exclusively on antibodies. However, there are no widely accepted guidelines or standardized methods to determine the validity of these reagents. Furthermore, many recent publications have highlighted the limitations of commercial antibodies, including failure to detect the intended target. The rigor and reproducibility of many assays commonly […]

NIH/NIDDK – Establishing a Cohort to Clarify Risk and Protective Factors for Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) – Planning Cooperative Agreements (U34 Clinical Trial Not Allowed)

There is growing evidence that there are neurocognitive complications of T1D, with approximately 28% of middle aged adults and 48% of older adults meeting criteria for clinically significant cognitive impairment (defined as performance =1.5 standard deviations below normative data on =2 cognitive tests). Early age of onset, duration of disease and severity of hyperglycemia (including […]

NIH/NCI – Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS). These PQs are not intended to represent the full range of NCI’s priorities in HIV/AIDS-related cancer research. […]